What is the drug thought to do in the body?
NB-4746 aims to block a protein called SARM1 in people living with MND. SARM1 is a protein that plays an important role in removing any damaged neurones from the nervous system. In people with MND, the SARM1 protein has been found to be overactive and is thought to damage neurones that are healthy. Research has suggested that blocking the SARM1 protein or reducing it’s activity might be able to protect healthy neurones from damage and could slow disease progression.
Phase 1/2 -
Current status: In preparation
Primary objective: To investigate the safety and effects of NB-4746 compared with placebo
This is the first in-human, randomised, double-blind study which is investigating the safety and tolerability of NB-4746 in people living with MND. The study has two parts to it. Part A is testing multiple doses of NB-4746 to determine the best one to use. In part A, participants will be randomly assigned to either receive a low dose, high dose or placebo (dummy drug) for one month. Part B of the trial will further test the best dose of the drug which was determined from part A. Participants in part B will be assigned to get either NB-4746 or a placebo for 12 weeks. Find out more on the MND Clinical Studies Group website or on a clinicaltrials.gov.
How can I take part in the trial?
Recruiting Sites
This trial is currently in the set up phase and sites are not yet open for recruitment.
Last updated: 29/05/2026